Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER

Name: .....

Ward: .....

PATIENT:

Name: .....

NHI: .....

Vanzacaftor with tezacaftor and deutivacaftor

INITIATION

Prerequisites (tick boxes where appropriate)

- ○ Patient has been diagnosed with cystic fibrosis

and

- ○ Patient has two cystic fibrosis-causing mutations in the cystic fibrosis transmembrane regulator (CFTR) gene (one from each parental allele)

or

- ○ Patient has a sweat chloride value of at least 60 mmol/L

and

- ○ Patient has a heterozygous or homozygous F508del mutation

or

- ○ Patient has a mutation responsive to vanzacaftor/tezacaftor/deutivacaftor (see note)

and

- ○ The treatment must be the sole funded CFTR modulator therapy for this condition

and

- ○ Treatment with vanzacaftor/tezacaftor/deutivacaftor must be given concomitantly with standard therapy for this condition

Note: Eligible mutations are listed in the in the Food and Drug Administration (FDA) Alyftrek prescribing information https://www.accessdata.fda.gov/drugsatfda_d

I confirm that the above details are correct:

Signed: ..... Date: .....